source
- Sanofi halts development of Kymab-derived OX40L antibody for atopic dermatitisSanofi announced that it will no longer pursue the OX40L antibody program it was developing with Kymab for the treatment of atopic dermatitis. The drug was being positioned as a potential follow‑on…
- Scribe Therapeutics raises $129 million in gene-editing IPO, debuting on NasdaqScribe Therapeutics completed an initial public offering that raised close to $129 million. The company sold 8.58 million shares at $15 each and will trade on Nasdaq under the ticker SCTX. The off…